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Background: Although intravenous saline is the accepted prophylactic measure for the prevention of contrast- induced
acute kidney injury, the oral route could offer an equivalent, practical, and cost saving approach. A systematic review of
randomized trials that compared oral versus intravenous volume expansion for the prevention of radiocontrast-induced
nephropathy in patients receiving arterial contrast reported no significant difference in the risk of contrast induced acute
kidney injury between the oral and intravenous arms. Most trials for contrast nephropathy prevention have been in the
setting of arterial contrast such as with cardiac catheterization, and not with venous contrast, such as computed
tomography. The aim of this paper is to describe the protocol of a pilot trial comparing the effect of oral salt and water
versus intravenous saline on the prevention of Acute Kidney Injury following contrast-enhanced computed tomography.
Methods: Our study is a pilot, single-centre parallel randomized controlled trial. To be included, participants must be
at stage 4 of chronic kidney disease as defined by a glomerular filtration rate <30 mL/min/1.73 m2, aged greater than
18 years and to undergo an outpatient contrast-enhanced computer tomography of the chest or abdomen. A total 50
patients will be randomised to receive either oral salt and water or intravenous isotonic saline. The primary outcome is
feasibility, including estimates of recruitment rate, adherence to intervention and completeness of follow-up to assist in
planning the definitive trial. The secondary outcome is safety and includes adverse events with oral salt and water
loading as compared to intravenous isotonic saline.
Discussion: The results of this pilot trial will provide critical information to plan a definitive trial to test the efficacy of
the route of volume loading regimens in prevention of acute kidney injury after contrast-enhanced CT scans.
Trial registration: The trial is registered at the US National Institutes of Health (ClinicalTrials.gov) # NCT02084771.
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Contexte: L’administration prophylactique de solution saline par voie intraveineuse est utilisée pour la prévention de
l’insuffisance rénale aiguë (IRA) secondaire aux produits de contraste iodés (PCI). Cependant, une administration par voie
orale pourrait être un traitement alternatif équivalent, pratique et économique. Une revue systématique des essais cliniques
à répartition aléatoire, qui comparaient les volémies post-administration orale, d’une part, et intraveineuse, d’autre part, de
solution saline dans la prévention des néphropathies secondaires aux PCI de patients qui recevaient un agent de contraste
par voie artérielle, a été effectuée. Aucun écart significatif en matière de risque d’IRA secondaire aux PCI n’a été observé
entre les deux groupes à l’étude. La plupart des essais traitant de prévention des néphropathies secondaire aux PCI ont été
effectués en contexte d’administration artérielle, comme par cathétérisme cardiaque, et non d’administration veineuse,
comme par tomodensitométrie. Le but de cet article est de décrire le protocole d’un essai comparatif pilote des effets d’
une solution saline administrée par voie orale à ceux d'une solution saline isotonique administrée par voie intraveineuse
dans la prévention de l’insuffisance rénale aiguë secondaire à la tomodensitométrie avec injection d’agent de contraste.
Méthode: Notre étude est un essai comparatif pilote, unicentrique, à répartition aléatoire. Seuls les participants atteints de
maladie rénale chronique de stade 4, définie par un débit de filtration glomérulaire < 30 ml/min/1,73m2, âgés de plus de
18 ans, et devant subir une tomodensitométrie avec agent de contraste du thorax ou de l’abdomen en clinique externe,
pourront faire partie de l’échantillon. L’administration d’eau salée par voie orale ou de solution saline isotonique par voie
intraveineuse sera répartie aléatoirement sur 50 patients. Les premières conclusions de l’étude aideront à planifier l’essai
définitif. Celles-ci concernent la faisabilité, dont les estimations du taux de recrutement, d’adhésion à l'intervention et
d’achèvement du suivi. Les conclusions secondaires se rapportent à la sécurité et font part, entre autres, d’une comparaison
des effets indésirables de l’administration orale d’eau salée et de l’administration intraveineuse de solution saline isotonique.
Discussion: Les résultats de cet essai pilote fourniront de l’information cruciale pour la planification de l’essai définitif visant
à tester l’efficacité des voies d’administration des traitements de prévention d’IRA après les tomodensitométries avec agent
de contraste.Background
Since its invention, computed tomography (CT) has
greatly improved diagnostics and patient care. Over 50%
CT procedures employ iodinated contrast material (CM)
[1]. At the same time as the CT scan use has rapidly in-
creased [2], it has been estimated that more than 80 mil-
lion doses of CM are administrated worldwide each year
[3]. Thus, since the number of CT scan examinations in-
crease, their adverse effects, including renal failure, also
potentially increase.
Acute kidney injury is a common form of nephropathy in-
duced by contrast medium reported by several studies
[4-10]. Contrast-induced acute kidney injury (CI-AKI) is as-
sociated with long- term adverse outcomes including stroke,
myocardial infarction, long term dialysis dependence, and
death [11-15]. The average in-hospital cost of CI-AKI is esti-
mated at $10,345 with the 1- year cost of treating a patient
with CI-AKI at $11,812 [16]. Thus, there is considerable
interest in developing strategies aimed at reducing the risk
of CI-AKI.
Hydration is clearly beneficial in prevention of CI-AKI
[17]. The Canadian guideline for chronic kidney disease pa-
tients who have contrast-enhanced computed tomography
scans is to give intravenous (IV) saline both before and after
their CT scan. Recommended protocols require that saline
be given in the one hour before and in the six hours follow-
ing contrast administration and have been formulated forarterial contrast (e. g. cardiac or peripheral angiography),
where patients do need a short stay for monitoring [18,19].
For contrast CT, this requires additional nursing time and
resources to monitor patients during the infusion (approxi-
mately 7–8 hours per patient). This regimen requires sig-
nificant health care resources as it requires a same-day
hospital stay, nursing time as well as patient inconvenience.
Oral salt and water solutions are well tolerated and ef-
fective in prevention and treatment of dehydration
[20-23]. Mechanistic studies have also established that oral
sodium and water loading results in rapid (within 20 mi-
nutes) changes in physiology with a significant increase in
cardiac output and subsequent diuresis [24-26]. We per-
formed a systematic review of randomized trials that com-
pared oral versus intravenous volume expansion for the
prevention of radiocontrast-induced AKI [27]. Our search
identified six small studies (average sample size n = 85), all
done in patients receiving arterial contrast [28-33]. We
pooled all six trials together in a meta-analysis and found
no significant difference in the odds of AKI between the
oral and intravenous fluid arms (summary odds ratio 1.2;
95% CI 0.46 to 3.10; P = 0.73). Taken together, these data
show that there is no clear trial evidence favouring intra-
venous over oral fluid expansion. Moreover, mechanistic
evidence suggests that a sufficient proportion of an acute
oral salt and water load is absorbed to have measurable
physiological effects within 30 minutes [24,34].
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vention have been in the setting of arterial contrast such as
with cardiac catheterization, and not with venous contrast,
such as computed tomography. The advantages of an oral
route of volume expansion in this setting would include de-
creased use of hospital resources and cost, reduced time in
hospital as well as improved patient comfort and conveni-
ence [33,35,36]. The 2012 guidelines from the Kidney Dis-
ease: Improving Global Outcomes (KDIGO) workgroup
state that, “if confirmed in larger studies, the oral strategy
could offer an equivalent and more practical approach in
preventing a decline in renal function after contrast expos-
ure, without accruing additional delay in hospital days or in-
hospital mortality” [37]. In addition, the trials we identified
in our systematic review were all small, none was powered
to study important clinical outcomes.
We are conducting a pilot randomized trial with the ob-
jective to measure the feasibility of a trial (recruitment, ad-
herence to intervention, completeness of follow up) and the
safety outcomes (adverse effects with the intervention). This
will provide crucial information required to facilitate the
planning of an adequately powered, definitive, randomized
controlled trial comparing the effect of oral salt and water
administration versus intravenous saline in the prevention
of CI-AKI occurring after an intravenous (IV) contrast ad-
ministration. This protocol describes the design and meth-
odology of the pilot randomized trial.
Methods
Design and setting
The study is designed as a single-centre, parallel-arm, ran-
domized controlled pilot trial. Participants will be recruited
from the Ottawa Hospital, an academic centre serving a
catchment area of 1.3 million residents in Eastern Ontario
(Ottawa and environs), Canada.
Participants
Participants will be identified within the medical imaging
department. Eligible patients are outpatients who are
scheduled for a contrast-enhanced CT scan of the chest
or abdomen. We plan to enrol 50 patients in this pilot
trial. Since this is a pilot trial to assess feasibility, we did
not carry out a formal sample size calculation. The rate
of recruitment in this trial will allow us to plan the re-
cruitment strategy and duration of the definitive trial.
For the large definitive trial (planned as a non-inferiority
trial) our preliminary estimates for sample size suggests
we need to recruit 1030 patients.
Criteria
Inclusion criteria
a) Chronic kidney disease (as defined by a glomerular
filtration rate (GFR) < 30 mL/min/1.73 m2 using theChronic Kidney Diseases (CKD)-EPI formula
calculated on the day of screening [38];
b) Undergoing an outpatient intravenous contrast-
enhanced CT of the chest or abdomen;
c) Age ≥ 18 years
Exclusion criteria
a) Inability to give informed consent;
b) Previously enrolled in this study;
c) Any contrast-enhanced test in previous 14 days (to
exclude patients who might have ongoing AKI from
previous contrast exposure);
d) Congestive heart failure defined as NYHA class III
or worse [39];
e) Uncontrolled hypertension defined as SBP greater
than 180 mm Hg or DBP greater than 110 mm Hg
at screening;
f ) Currently receiving dialysis treatments.
g) The physician ordering the CT scan has specifically
ordered intravenous saline, sodium bicarbonate or
n-acetyl cysteine.
h) Scheduled to receive oral contrast solution as part of
CT scan procedure
Patient identification and recruitment
A chart review will be performed on all patients with
scheduled contrast-CT scans of the chest or abdomen
by department personnel. Potential participants will be
approached by phone calls as per local study-specific
Research Ethical Board -approved procedures and
Standard Operating
Procedures. Potential participants who consent will be
invited for a screening visit where they will be asked to
give a blood sample to analyze their serum creatinine
(SCr) levels. This will serve to calculate the estimated GFR
used in the screening process. Final inclusion/exclusion
criteria will be assessed and confirmed by the Principal In-
vestigator and Co-Investigator only. Consenting patients
fulfilling entry criteria will be successively recruited. The
Consolidated Standards of Reporting Trials flow diagram
will be used to show the study flow chart (Figure 1.)
Randomization and allocation concealment
Patients will be randomized to receive either oral salt and
water or intravenous saline. The randomization process will
consist of a computer generated random listing of the treat-
ment allocations in permuted blocks of varying size. For ex-
ample, given a block size of 4 patients recruited, there will
be 2 allocations to oral salt and water arm and 2 to the
intravenous saline arm. The system will have backup in the
form of an independent statistician who will be informed
and able to issue the treatment allocation in the event of a
system malfunction/shutdown.
Figure 1 Study flow chart.
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by a statistician after eligibility is documented by the
Principal Investigator/Co-Investigators based on inclusion/
exclusion criteria and after the patient signs the informed
consent. From the computer random listing a code will be
assigned to each new subject. This randomization code is a
participant unique identifier (ID) and corresponds to the
study treatment that will be given to the patient. Patient will
be considered randomized as soon as the randomization
code is given. All patients who are allocated a randomization
code (i.e., study treatment number) will be irrevocably in the
study and they will be followed until the end of study,
loss to follow-up or death whichever comes first. The
randomization codes corresponding to the participant ID
will be printed and put in numbered sealed envelopes. On
the day of the CT scan, these envelopes will be delivered tothe imaging room to be opened by the Principal Investigator
who will administer the trial treatment.
Blinding
Blinding of the intervention is extremely difficult as one
intervention will be oral and the other intravenous. A
double-dummy design could be considered but the
“dummy” intravenous fluid would likely have some volume
expanding effect that could affect the outcome. Aside from
the ethical consideration, a sham infusion could be consid-
ered but may prove difficult with back flow of blood from
the venous cannula if no infusion were occurring. To
minimize co- interventions that might be given once treat-
ment assignments are known, participants, radiology staff
and the ordering physician will not be informed of the
treatment assignment prior to the scheduled CT, which will
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itional therapies based on knowledge of the treatment as-
signment. All trial interventions will be administered by the
Principal Investigator out of sight of imaging staff.
Trial intervention and dosing
The oral salt and water arm
Participants randomized to this arm of the trial will receive
0.1 g/kg of salt (NaCl) in capsule form and 12 mL/kg of
water. Patients weighing more than 110 kg will receive the
same amount as per a 110 kg patient [18]. This dosage was
based on the trial of Dussol et al. in which oral salt was
given using a pre-specified, weight-based approach [32].
This trial showed that 50% more oral salt ingestion, com-
pared to intravenous saline, produced equivalent urinary
sodium excretion. We have used these proportions to for-
mulate the equivalent oral salt dosing. The oral water dosing
has been calculated to make the overall composition ap-
proximately isotonic similar to the intravenous saline arm.
One third of the oral salt and water will be given in 1 hour
before the CT and 2/3 in the 2 hours post-CT. Specifically,
0.03 g/kg of NaCl and 4 mL/kg of water in the one hour be-
fore CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken
over 2 hours post-CT. The salt capsule and water will be
taken in presence of the research personnel who will record
on an assessment form that the patient has received the
intervention (ingested the oral salt and water).
The intravenous saline arm
Patients randomized to this arm will receive IV isotonic
(0.9%) saline which is the standard of care recommended
by Canadian [19] and international guidelines [8,40-44].
The rate of isotonic saline will be 3 mL/kg given in the one
hour before CT and 1 mL/kg/hour for 6 hours post-CT as
per Canadian guidelines [19]. Patients weighing more than
110 kg will receive the rate as per a 110 kg patient [18].
The dose will be rounded up to the nearest 5 mL.
Data collection
At baseline, participant demographic information (in-
cluding ethnicity, sex, month and year of birth), CT scan
characteristics, medical history and medication use will
be recorded. On the day of the CT scan, before oral or
IV fluids are given, a SCr will be measured that will be
considered as the baseline value. A subsequent SCr level
will be measured at 48 hours post-CT. If the SCr at
48 hours has increased by ≥25% or ≥44 μmol above the
baseline value, the SCr will be repeated every 48 hours
until it returns to within 25% of baseline or < 44 μmol
above baseline or the patient needs to initiate acute dia-
lysis. If the SCr has not returned to within 25% of base-
line or < 44 μmol above baseline by day 14 post-CT, the
SCr will be measured again on day 21. All participants
(regardless of whether they developed AKI) will haveSCr repeated on day 28 post- CT (Figure 2). The SCr
will be measured in the biochemistry lab at the Ottawa
Hospital. The repeat creatinine measurements, though
underpowered for any assessment of efficacy, will allow
us to ascertain the proportion of patients who follow-up
at each time point, which will be critical for our larger
definitive trial. The study timeline is shown in Table 1.
Outcomes
Feasibility of conducting the definitive trial is the primary
outcome for this pilot study. It will be determined by the
proportion of patients who will 1) consent to enrolment in
the study (recruitment rate), 2) complete the fluid ingestion
at dose required in both arms (adherence to intervention),
and 3) complete repeat measures of creatinine at 48 hours
and 28 days (follow-up). Additionally, we will identify logis-
tical issues related to screening, protocol implementation,
randomization implementation strategy, time, and budget
problems that can occur during the definitive trial.
The secondary outcome for this pilot trial is safety. It
will be assessed by adverse effects occurring after re-
ceiving the trial treatment. Adverse effects that may
occur because of the ingestion of water and salt include:
nausea or gastrointestinal symptoms. Symptoms that
may occur because of the saline solution or the tech-
nique of administration include discomfort with the
venipuncture at the site of injection such as skin
irritation and pain, hemorrhage, hematoma, thrombosis,
phlebitis. All adverse events effects will be assessed by
patients self-reported symptoms using a questionnaire
with these symptoms listed and will be recorded in a
Case Report Form at the end of the volume expansion
protocol.
Ethical issues and trial registration
The pilot trial will be conducted in accordance with
Health Canada’s Good Clinical Practice guidelines [45]
in accordance with the current Declaration of Helsinki
and the Tri-Council Policy Statement: Ethical Conduct
for Research Involving Humans [46]. All patients will be
informed that they can withdraw from the study at any
time. Patients who agree to participate to the study will
provide a written informed consent. The study protocol
and informed consent forms have been approved by the
Ottawa Health Science Network Research Ethics Board.
The trial is registered at the US National Institutes of
Health (ClinicalTrials.gov) # NCT02084771.
Statistical analyses
Baseline analyses
Baseline characteristics of patients in the two treatment
arms will be assessed by calculation of frequency distri-
butions and univariate descriptive statistics including
measures of central tendency and dispersion.
Figure 2 Repeat creatinine test schedule.
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For the recruitment rate, we will calculate the proportion
(and 95% confidence interval) of all CKD stage 4 patients
who are randomized into the trial among those who
undergo a contrast-enhanced CT scan of the abdomen or
chest. In addition, we will calculate the proportion of pa-
tients that were eligible but who declined consent, those
who were eligible but were not approached. For the feasibil-
ity outcome of adherence, we will calculate the proportion
of patients who will complete the fluid ingestion in both
arms out of all those recruited. The follow- up will be mea-
sured by calculating the proportion of participant recruitedwho complete the follow-up (the proportion of patients who
will undergo repeat measures of creatinine at 48 hours and
28 days among those recruited). Proportion of patients who
will be adherent and those who will complete the follow-up
will be compared between the arms with an unadjusted chi-
square, or with Fisher’s exact test if the cell sizes are small.
Safety
For the safety outcome, we will calculate the frequency of
overall adverse events that will occur in each trial arm and
we will compare them using an unadjusted chi-square test
or Fisher’s exact test. Univariate descriptive statistics
Table 1 Study timeline
Study period
Enrolment Allocation Post allocation Close-out
-t1 o Day1 Day2 Day3 Day4 etc. Day28
Enrolment:
Eligibility screen X
Informed consent X
Demographic data collection X
Medication use data collection X
serum creatinine testing X X X
Allocation X
Interventions:
Intravenous saline solution X
Oral salt water X
Assessments:
Adherence to intervention X X
Adverse events X
serum creatinine testing X X
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be used to report the frequency of adverse events. This
outcome will be underpowered to draw any definite con-
clusions, but will be conducted to help us design the de-
finitive trial.
Study management and patient safety
A trial management group involving the Principal investiga-
tor (SH), two Co-investigators (AA, GK) and study coordin-
ator (EM) will review, implement and supervise all aspects
of this pilot trial. The Data Management Services group of
the Ottawa Hospital Research Institute will generate the ran-
dom listing. Under the guidance of the Principal investigator
and the study coordinator, the coordinating centre located
at the Clinical Epidemiology Program of the Ottawa Hos-
pital Research Institute will be responsible for receiving, pro-
cessing, editing storing and analyzing all data.
A DSMB will have responsibility for the monitoring of ad-
verse events throughout the study and will work independ-
ently from the trial. The DSMB will consist of three
individuals with expertise in clinical trials, biostatistics,
nephrology and radiology. All serious adverse events will be
reported to and reviewed by the DSMB. The DSMB will rec-
ommend termination or continuation of the study in the
event of an unexpected adverse event rate.
All investigational products supplies in the study will be
stored in a secure, safe place, under the responsibility of the
Investigator.
Discussion
The proposed project is a pilot trial of a simple pragmatic
intervention (oral salt and water) in comparison to thestandard of care (intravenous saline) for prevention of acute
kidney injury after IV contrast administration. The results of
our pilot study will provide crucial data to the planning of a
large multicentre randomized trial to determine if oral salt
and water administration is as effective as intravenous sa-
line in the prevention of radiocontrast-induced AKI oc-
curring after an IV contrast administration. For this
definitive trial, we will study efficacy (incidence of AKI) as
primary outcomes, with secondary outcomes including
clinical (hospitalization, need for dialysis, and mortality)
and health services aspects (economic analysis). A lower
recruitment rate in the pilot trial will help us to plan
adding more sites or a longer recruitment period for the
definitive trial. Protocol adherence and follow-up mea-
surements will provide additional feasibility information
to plan refinement of the final protocol as well as adjust
sample size estimates for a larger trial. Knowledge of the
frequency and severity of the adverse events will be used
by the trial management group to determine if the poten-
tial benefits of conducting a larger trial outweigh the po-
tential risks with the proposed intervention in a larger
trial.
Trial status
This pilot trial was designed in 2012–2013 and received
a grant from the Department of Medicine of the Univer-
sity of Ottawa. Recruitment started in October 2014.
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